Published in Cancer Weekly, May 8th, 1995
The study reported that the median survival time (MST) of 30 Phase II Onconase-treated patients was 7.7 months longer than the majority of other published single agent and combination chemotherapy clinical trials.
The MST of patients who received either supportive care or a placebo, in the studies reported, ranged from 1.9 months to 4.8 months. MST of the reported single agent chemotherapy trials range from 4.0 to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.